baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Celldex Therapeutics/ US15117B2025 /

2024-04-19 9:38:03 PM	Chg. -0.97	Volume	Bid-	Ask-	High	Low
37.53USD	-2.51%	17,663 Turnover: 661,615.97	-Bid Size: -	-Ask Size: -	38.49	36.84

GlobeNewswire 04-17 Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chroni...

GlobeNewswire 03-08 Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

GlobeNewswire 03-05 Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference

GlobeNewswire 03-05 Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Under...

GlobeNewswire 03-01 Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock

GlobeNewswire 02-28 Celldex Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire 02-26 Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update

GlobeNewswire 02-24 Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic S...

GlobeNewswire 02-06 Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire 02-05 Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urti...

GlobeNewswire 2023-12-27 Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

GlobeNewswire 2023-12-07 Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

GlobeNewswire 2023-11-27 Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference

GlobeNewswire 2023-11-08 Celldex Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire 2023-11-07 Celldex Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire 2023-11-06 Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic ...

GlobeNewswire 2023-11-05 Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Mean...

GlobeNewswire 2023-11-02 Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire 2023-09-26 Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at ...

GlobeNewswire 2023-09-26 Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Inn...

GlobeNewswire 2023-09-25 Celldex Therapeutics to Present at Cantor Global Healthcare Conference

GlobeNewswire 2022-02-28 Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

GlobeNewswire 2022-02-22 Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Confere...

GlobeNewswire 2022-02-10 Celldex to Present at the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire 2021-12-17 Coherus BioSciences Appoints Theresa LaVallee, Ph.D., Chief Development Officer

Celldex Therapeutics/ US15117B2025 /

If you wish to receive reply to your feedback, please provide your email address.